SCHEDULE: BlackRock Boosts Stake in Stoke Therapeutics to 6.8%

BlackRock, Inc. has reported an increased beneficial ownership of 6.8% in Stoke Therapeutics, Inc. common stock as of September 30, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 2 to Schedule 13G for Stoke Therapeutics, Inc.
• BlackRock, Inc. beneficially owns 3,732,540 shares of Stoke Therapeutics, Inc. common stock.
• This represents 6.8% of the class of securities.
• BlackRock holds sole voting power over 3,666,122 shares and sole dispositive power over 3,732,540 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• BlackRock, Inc. has updated its Power of Attorney, effective January 21, 2025, authorizing specific individuals to execute SEC filings on its behalf.

Sentiment

Score: 7

Explanation: The filing indicates a significant and stable institutional investment by BlackRock, a positive signal of confidence in Stoke Therapeutics. No negative information is presented.

Positives

• BlackRock, a major institutional investor, maintains a significant stake (6.8%) in Stoke Therapeutics, indicating continued confidence.
• The holding is for investment purposes in the ordinary course of business, not for control, suggesting a stable passive investment.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Stoke Therapeutics, Inc.'s future performance or BlackRock's future investment intentions beyond the current ownership disclosure.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

The filing reflects a significant institutional investment by BlackRock in Stoke Therapeutics, a biotechnology company. Such large stakes by major asset managers are common across the biotech sector, indicating investor interest in companies with promising pipelines or market positions. This specific filing does not provide broader industry trends but highlights continued institutional confidence in the issuer.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding a major institutional investor's stake, potentially influencing market perception and liquidity.
• Management: Awareness of significant institutional ownership can influence strategic decisions and investor relations.

Next Steps

• No specific future actions or milestones for Stoke Therapeutics are mentioned in this ownership disclosure. BlackRock's next steps would be to file further amendments if their ownership percentage changes significantly.

Key Dates

Recommendation

This Schedule 13G filing indicates BlackRock's continued significant beneficial ownership in Stoke Therapeutics, Inc. at 6.8%. While a large institutional stake can be seen as a vote of confidence, this filing is purely a disclosure of ownership and does not provide new operational or financial performance data for Stoke Therapeutics. Therefore, it does not present a basis for a 'buy' or 'sell' recommendation, but rather reinforces a 'hold' position for existing investors, acknowledging the presence of a major institutional holder without new catalysts for price movement.

Keywords

Stoke Therapeutics, BlackRock, Schedule 13G, Institutional Ownership, Common Stock, Biotechnology, Investment, Equity Stake